4D Molecular Therapeutics, Inc. Operating Lease, Expense
4D Molecular Therapeutics, Inc. (FDMT) reported Operating Lease, Expense of $2.60 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-03-28
- 4D Molecular Therapeutics, Inc. operating lease, expense for the quarter ending 2021-12-31 was $300.00K, a 57.14% decline year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, expense for the quarter ending 2021-09-30 was $800.00K, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, expense for the quarter ending 2021-06-30 was $800.00K, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, expense for the quarter ending 2021-03-31 was $800.00K, a 0.00% change year-over-year.
- 4D Molecular Therapeutics, Inc. operating lease, expense for fiscal 2021 was $2.60M, a 13.33% decline from fiscal 2020.
- 4D Molecular Therapeutics, Inc. operating lease, expense for fiscal 2020 was $3.00M, a 130.77% increase from fiscal 2019.
- 4D Molecular Therapeutics, Inc. operating lease, expense for fiscal 2019 was $1.30M.
| Period end | Operating Lease, Expense 1 month | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.10M derived: sum of 2 quarters · filed 2022-03-28 | $1.90M derived: sum of 3 quarters · filed 2022-03-28 | $2.60M 10-K · filed 2022-03-28 | |
| 2021-09-30 | $800.00K 10-Q · filed 2021-11-10 | $1.60M derived: sum of 2 quarters · filed 2021-11-10 | $2.30M 10-Q · filed 2021-11-10 | $3.10M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2021-06-30 | $800.00K 10-Q · filed 2021-08-12 | $1.50M 10-Q · filed 2021-08-12 | $2.30M derived: sum of 3 quarters · filed 2021-08-12 | $3.10M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2021-03-31 | $800.00K 10-Q · filed 2021-05-13 | $1.50M derived: sum of 2 quarters · filed 2021-05-13 | $2.30M derived: sum of 3 quarters · filed 2021-11-10 | $3.10M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.50M derived: sum of 2 quarters · filed 2021-11-10 | $2.30M derived: sum of 3 quarters · filed 2021-11-10 | $3.00M 10-K · filed 2021-03-25 | |
| 2020-09-30 | $800.00K 10-Q · filed 2021-11-10 | $1.60M derived: sum of 2 quarters · filed 2021-11-10 | $2.30M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $800.00K 10-Q · filed 2021-08-12 | $1.50M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $800.00K 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $1.30M 10-K · filed 2021-03-25 | ||||
| 2019-05-31 | $1.00M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |